85 phenotypes from 12 alleles in 20 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cnr1tm1.1(KOMP)Vlcg/Cnr1+ C57BL/6N-Cnr1tm1.1(KOMP)Vlcg/MbpMmucd	edema	J:211773
Cnr1tm1.1(KOMP)Vlcg/Cnr1+ C57BL/6N-Cnr1tm1.1(KOMP)Vlcg/Ucd	abnormal behavior	J:211773
	abnormal skin morphology	J:211773
	decreased thigmotaxis	J:211773
	hyperactivity	J:211773
Cnr1tm1.1(KOMP)Vlcg/Cnr1tm1.1(KOMP)Vlcg C57BL/6N-Cnr1tm1.1(KOMP)Vlcg/MbpMmucd	edema	J:211773
Cnr1tm1.1(KOMP)Vlcg/Cnr1tm1.1(KOMP)Vlcg C57BL/6N-Cnr1tm1.1(KOMP)Vlcg/Ucd	preweaning lethality, complete penetrance	J:211773
	preweaning lethality, incomplete penetrance	J:211773
Cnr1tm1.1Kpm/Cnr1tm1.1Kpm involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	abnormal cerebral cortex morphology	J:208116
	abnormal neuron physiology	J:208116
	abnormal synaptic plasticity	J:208116
	increased behavioral withdrawal response	J:208116
	increased chemically-elicited antinociception	J:208116
	increased physiological sensitivity to xenobiotic	J:208116
Cnr1tm1.1Ltz/Cnr1+ involves: 129P2/OlaHsd * C57BL/6N	increased susceptibility to pharmacologically induced seizures	J:89842
Cnr1tm1.1Ltz/Cnr1tm1.1Ltz B6.129P2-Cnr1tm1.1Ltz	abnormal axon fasciculation	J:171771
	abnormal learning/memory/conditioning	J:77936
	abnormal nervous system development	J:171771
	abnormal nervous system morphology	J:171771
	abnormal paired-pulse facilitation	J:77936
	absent long-term depression	J:77936
	normal behavior/neurological phenotype	J:77936
	decreased exploration in new environment	J:77936
	enhanced long-term potentiation	J:77936
	normal nervous system phenotype	J:171771
Cnr1tm1.1Ltz/Cnr1tm1.1Ltz involves: 129P2/OlaHsd * C57BL/6N	increased susceptibility to pharmacologically induced seizures	J:89842
	increased susceptibility to xenobiotic induced morbidity/mortality	J:89842
Cnr1tm1.1Pcn/Cnr1tm1.1Pcn Tg(Phox2b-cre)1Jke/0 involves: 129 * C57BL/6J	abnormal gastrointestinal motility	J:186542
	normal behavior/neurological phenotype	J:186542
	normal growth/size/body region phenotype	J:186542
	normal homeostasis/metabolism phenotype	J:186542
Cnr1tm1.2Ltz/Cnr1tm1.2Ltz involves: 129P2/OlaHsd * C57BL/6NCrl	increased susceptibility to pharmacologically induced seizures	J:122066
Cnr1tm1.2Ltz/Cnr1tm1.2Ltz Neurod6tm1(cre)Kan/Neurod6+ involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6NCrl	abnormal axon fasciculation	J:171771
	abnormal impulsive behavior control	J:179495
	abnormal nervous system development	J:171771
	abnormal response to novel object	J:179495
	increased susceptibility to pharmacologically induced seizures	J:122066
Cnr1tm1.2Ltz/Cnr1tm1.2Ltz Tg(Camk2a-cre)2Gsc/0 involves: 129P2/OlaHsd * C57BL/6N	increased susceptibility to neuronal excitotoxicity	J:89842
	increased susceptibility to pharmacologically induced seizures	J:89842
	increased susceptibility to xenobiotic induced morbidity/mortality	J:89842
Cnr1tm1.2Ltz/Cnr1tm1.2Ltz Tg(Camk2a-cre)2Gsc/? involves: 129P2/OlaHsd * C57BL/6NCrl * FVB/N	abnormal impulsive behavior control	J:179495
	abnormal response to novel object	J:179495
	increased susceptibility to pharmacologically induced seizures	J:122066
Cnr1tm1.2Ltz/Cnr1tm1.2Ltz Tg(dlx5a-cre)1Mekk/? involves: 129P2/OlaHsd * C57BL/6NCrl * CD-1	abnormal inhibitory postsynaptic currents	J:122066
	normal behavior/neurological phenotype	J:122066
Cnr1tm1.2Ltz/Cnr1tm1.2Ltz Tg(dlx5a-cre)1Mekk/? involves: 129P2/OlaHsd * CD-1	abnormal cerebral cortex morphology	J:121856
Cnr1tm1Dgen/Cnr1tm1Dgen involves: 129S1/Sv * 129X1/SvJ	impaired behavioral response to xenobiotic	J:144774
Cnr1tm1Dgen/Cnr1tm1Dgen involves: 129S1/Sv * 129X1/SvJ * ICR	normal nervous system phenotype	J:143885
	reduced long-term depression	J:144773
Cnr1tm1Lex/Cnr1tm1Lex involves: 129S5/SvEvBrd * C57BL/6J	decreased percent body fat/body weight	J:185494
Cnr1tm1Map/Cnr1+ involves: 129S1/Sv * 129X1/SvJ * CD-1	increased cerebral infarct size	J:109213
Cnr1tm1Map/Cnr1tm1Map B6.129-Cnr1tm1Map	abnormal nervous system physiology	J:156514
	abnormal sweet taste sensitivity	J:156514
Cnr1tm1Map/Cnr1tm1Map involves: 129S1/Sv * 129X1/SvJ	abnormal bone mineral density	J:105218
	abnormal inhibitory postsynaptic currents	J:109305
	enhanced long-term potentiation	J:60079
	increased bone mineral density	J:105218
	increased sperm motility	J:123226
	normal skeleton phenotype	J:105218
Cnr1tm1Map/Cnr1tm1Map involves: 129S1/Sv * 129X1/SvJ * CD-1	abnormal active avoidance behavior	J:103942
	abnormal depression-related behavior	J:103942
	abnormal neuronal precursor proliferation	J:102006
	abnormal response to novel object	J:52188
	abnormal social/conspecific interaction behavior	J:89722
	anhedonia	J:103942
	hyperactivity	J:52188
	impaired behavioral response to addictive substance	J:52188
	impaired behavioral response to morphine	J:52188
	impaired conditioned place preference behavior	J:52188
	increased aggression towards mice	J:89722, J:103942
	increased anxiety-related response	J:89437, J:89722, J:103942
	increased cerebral infarct size	J:109213
	increased circulating adrenocorticotropin level	J:89722
	increased exploration in new environment	J:52188
	increased locomotor activity	J:52188
	increased physiological sensitivity to xenobiotic	J:172874
	increased susceptibility to induced morbidity/mortality	J:109213
	increased susceptibility to ischemic brain injury	J:109213
	increased susceptibility to neuronal excitotoxicity	J:109213
Cnr1tm1Ojm/Cnr1tm1Ojm involves: 129P2/OlaHsd * C57BL/6	abnormal excitatory postsynaptic potential	J:93698
	abnormal food intake	J:93697
	absent long-term depression	J:93698
	decreased body weight	J:93697
	decreased circulating insulin level	J:93697
	decreased circulating leptin level	J:93697
	decreased susceptibility to diet-induced obesity	J:93697
	decreased total body fat amount	J:93697
	increased insulin sensitivity	J:93697
	weight loss	J:93697
Cnr1tm1Zim/Cnr1tm1Zim involves: 129 * C57BL/6J	catalepsy	J:54995
	decreased circulating progesterone level	J:144423
	decreased locomotor activity	J:54995, J:55294
	decreased survivor rate	J:54995
	decreased vertical activity	J:55294
	early parturition	J:144423
	hypoalgesia	J:54995
	impaired behavioral response to addictive substance	J:54995
	increased chemical nociceptive threshold	J:54995
	increased circulating corticosterone level	J:144423
	increased circulating estradiol level	J:144423
	increased follicle stimulating hormone level	J:144423
	increased thermal nociceptive threshold	J:54995
	maternal effect	J:144423
	postnatal lethality, incomplete penetrance	J:54995
	premature death	J:54995
Cnr1tm2.1Ltz/Cnr1tm2.1Ltz B6.Cg-Cnr1tm2.1Ltz	no abnormal phenotype detected	J:199647
Cnr1tm2Ltz/Cnr1tm2.1Ltz Neurod6tm1(cre)Kan/Neurod6+ B6.Cg-Cnr1tm2Ltz/Cnr1tm2.1Ltz	abnormal cued conditioning behavior	J:199647
	normal behavior/neurological phenotype	J:199647
	decreased synaptic depression	J:199647
	increased susceptibility to xenobiotic induced morbidity/mortality	J:199647
Cnr1tm2Ltz/Cnr1tm2Ltz B6.Cg-Cnr1tm2Ltz	abnormal cued conditioning behavior	J:199647
	decreased synaptic depression	J:199647
	impaired cued conditioning behavior	J:199647
	increased anxiety-related response	J:199647
	increased susceptibility to pharmacologically induced seizures	J:199647
	increased susceptibility to xenobiotic induced morbidity/mortality	J:199647